Adrian Hugenmatter

Adrian Hugenmatter

Director of Protein Therapeutics, Sarafan ChEM-H
Mail Code: none

Dr. Hugenmatter received his PhD in the laboratory of Prof. Donald Hilvert at the Swiss Federal Institute of Zurich (ETH Zurich, Switzerland), where he gained initial experience in enzymology, antibody engineering and directed evolution. Fascinated by protein engineering, he joined the laboratory of Prof. Dan Tawfik at the Weizmann Institute of Science (Israel), where he studied molecular evolution and its application in protein design. Afterwards, Dr. Hugenmatter worked as a research scientist and team leader at Roche for more than a decade. During that time, he was involved in the development and optimization of several antibody lead candidates for therapeutic applications in neuroscience and oncology. Throughout his career, Dr. Hugenmatter is driven by the desire to develop medicines with the greatest possible benefit for the patient. At Stanford, he also leads the Protein Engineering Knowledge Center at Sarafan ChEM-H. At both Sarafan ChEM-H and the IMA, he and his team collaborate with PIs from across Stanford to accelerate drug discovery based on groundbreaking discoveries.